Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
Guillaume Le GuyaderVictoire VieillardMuriel PaulPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
The trastuzumab biosimilar MYL-1401O maintained its physical and chemical stability for at least 90 days at 4°C or after thermal excursion to 25°C, supporting the safe use of MYL-1401O in several real-world settings, including advanced preparation for administration or when a break in the cold cycle occurs.